ArticleAntimicrobial agents and chemotherapy2007
Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Synergistic activity of caspofungin and posaconazole againstMicrobiology spectrum · 2026Article
- Retrospective analysis of the role of retrobulbar amphotericin-B injection in the management of COVID-19 associated rhino-orbito-cerebral-mucormycosis.The Pan African medical journal · 2022Article
- In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs onJournal of fungi (Basel, Switzerland) · 2021Article
- Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread.Frontiers in microbiology · 2021Review
- The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.Antimicrobial agents and chemotherapy · 2015Article
- Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Clinical pharmacokinetics · 2014Review
- Drug combinations against Mucor irregularis in vitro.Antimicrobial agents and chemotherapy · 2013Article
- Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.Clinical microbiology reviews · 2011Review
- Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.British journal of clinical pharmacology · 2010Article
- Internal transcribed spacer region sequence heterogeneity in Rhizopus microsporus: implications for molecular diagnosis in clinical microbiology laboratories.Journal of clinical microbiology · 2010Article
- Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia.Journal of clinical microbiology · 2009Article
- Outbreak of intestinal infection due to Rhizopus microsporus.Journal of clinical microbiology · 2009Article
- In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.Antimicrobial agents and chemotherapy · 2009Article
- Treatment options in emerging mold infections.Current infectious disease reports · 2008Article
- Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.Antimicrobial agents and chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.